Neuraptive Therapeutics appoints new director to the board

Neuraptive Therapeutics, a Philadelphia biotech dedicated to developing novel therapeutics and medical products for patients with nerve injuries, has announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.

Dr. Ruffolo has over 40 years of research and development experience and is currently the Chairman of Aragen Biosciences, Inc. and Managing Director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries. Dr. Ruffolo is the retired President of Research and Development of Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer). He managed an R&D organization of 9,000 scientists with an annual budget in excess of $5bn.

Prior to Wyeth, Dr. Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories. He earned his Ph.D. in Pharmacology and his B.S. in Pharmacy from The Ohio State University.